Introduction
With the advent of proton pump inhibitor (PPI) based triple therapies initiated by Bell et al 1 and Bazzoli et al 2 , a new standard of Helicobacter pylori treatment eYcacy has been set. This has been recently integrated into the recommendations of the Maastricht Consensus Report 1996.
3 On 12-14 September 1997, Lisbon hosted the Xth International Workshop on Gastroduodenal Pathology and Helicobacter pylori, the oYcial international meeting of the European Helicobacter pylori Study Group. A section of this meeting has traditionally been devoted to therapy, and this year it comprised 67 accepted abstracts.
Abstracts addressing the following issues are reviewed. Are any alterations of the dosage, the duration or the number of agents able to optimise the current standard? Is the application of the standard in routine practice as eYcacious as in scientific studies and is it cost-eVective? What are the predictors of treatment success? Emphasis is placed on microbial resistance which leads to the issue of second line treatment.
Forty two abstracts presented original data on therapeutic trials with 54 treatment arms. The results of seven day treatment arms grouped for the main combinations of antimicrobial agents are given in figures 1-3.
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Is more better?
DOSE OF MACROLIDE
The optimum dose of clarithromycin in PPI triple therapies is still debatable, as randomised studies indicate that, on the one hand, the minimum dose is diVerent depending on the other components, 24 25 and, on the other, side eVects such as taste disturbances and diarrhoea are controlled mainly by the dose. 24 25 The dose of clarithromycin was the subject of a meta-analysis by Huang et al. 26 Analysing 26 treatment arms of one week triple therapies with PPI, clarithromycin, and metronidazole, they found that 500 mg clarithromycin twice a day resulted in a significantly higher H pylori cure rate (90% intention to treat (ITT)) than 250 mg twice a day (82% ITT). The same holds true for the triple therapy with PPI, clarithromycin, and amoxycillin (91% v 80% ITT). A drawback of this meta-analysis is that no data were provided on the randomisation. An earlier randomised study indicated that 250 mg clarithromycin is equivalent in the combination PPI, clarithromycin, and metronidazole. 24 When used in combination with lansoprazole and amoxycillin, Yang et al 10 found that 250 mg clarithromycin was satisfactory only when used for two weeks (92% per protocol (PP)), but 500 mg was still more eVective (96% PP). Clarithromycin in combination with a PPI and a nitroimidazole may be replaced by azithromycin without loss of eYcacy. Whereas Caselli et al 27 achieved a 93% eradication rate using azithromycin 500 mg for three days, Seelis et al 28 achieved only 47% with the same dose, but 93% using azithromycin 500 mg for six days. originally used a once daily standard dose. Three abstracts of large studies investigating the dose of PPI clearly support the Maastricht recommendation. In a randomised study by Buda et al, 20 two daily doses of 30 mg lansoprazole proved to be significantly more eYcacious (88% PP, 83% ITT) than 15 mg twice a day (76% PP, 71% ITT) in combination with clarithromycin and amoxycillin. Applying the same antibiotics in a randomised study, Lamouliatte et al 21 found pantoprazole 40 mg to be significantly superior when used twice a day (81% PP) compared with a once daily dosage (59%). In combination with metronidazole and amoxycillin, omeprazole 40 mg yielded a higher H pylori cure rate (74%) than omeprazole 20 mg (67%). 23 Further evidence was provided that 400 mg ranitidine bismuth citrate is equivalent to a standard dose of PPI in triple therapy.
11 14 22 29 In dual therapy with clarithromycin it may be even superior to PPI.
29

Is longer better?
The issue of treatment duration turned out to be rather controversial in the Lisbon abstracts. Most studies confirmed that one week of treatment is suYcient in PPI triple therapy, but there may be some exceptions that are potentially due to regional diVerences or disease entity. No benefit from a longer treatment period was found in the following studies: in Italy with ranitidine bismuth citrate and clarithromycin, 7 v 14 days 30 ; in the USA with lansoprazole, clarithromycin, and amoxycillin, 10 v 14 days 31 ; in Spain with omeprazole, clarithromycin, and amoxycillin, 6 v 12 days for peptic ulcer disease 32 ; and in Germany with pantoprazole, clarithromycin, and metronidazole 7 v 14 days. 12 Significantly higher H pylori cure rates with longer treatments were achieved in Croatia 16 with omeprazole, amoxycillin, and metronidazole as well as with omeprazole, clarithromycin, and amoxycillin (7 v 14 days), in Spain with omeprazole, clarithromycin, and amoxycillin (6 v 12 days) for patients with non-ulcer gastritis, 32 and in Taiwan 10 with lansoprazole, clarithromycin 250 mg once daily, and amoxycillin (7 v 14 days). In the last of these studies, however, the dose of clarithromycin used was below the standard. None of these studies provided data on resistance. In contrast, reducing treatment duration to less than one week has proved to be disadvantageous. 28 33 34 Are more agents better? Authors presenting studies on quadruple or even quintuple therapies intended to increase the eradication rate further, to reduce the treatment time, or to establish a second line treatment after failure of H pylori eradication. No convincing data have been provided to support the notion that the use of more than three agents is superior as a first line treatment in eradicating H pylori.
The quadruple therapy of PPI, bismuth, metronidazole, and tetracyclin, introduced by Hosking et al, 35 de Boer et al, 36 37 and Borody et al, 38 is highly eYcacious when used as an initial treatment and when the high numbers of tablets are taken for one week. Reducing the treatment duration to four or two days has now been shown to lead to a loss of eYcacy, particularly in patients harbouring a metronidazole resistant strain. 33 34 A treatment introduced by Daskalopoulos et al 39 using the five agents colloidal bismuth subcitrate, tetracyclin, metronidazole, roxithromycin, and lansoprazole resulted in a higher eradication rate than with three or four of these agents, but the rate achieved did not exceed 92% PP. Moreover, the agents were given for two weeks and no data on side eVects were presented.
After failure of dual therapy, the combination of omeprazole with not only two but all three standard antimicrobial agents, all given for five days, was no more eYcacious (93% PP, 90% ITT) than omeprazole, clarithromycin, and metronidazole for seven days. 8 Another two groups presented studies on newly created quadruple therapies as second line treatments. The eradication rates were satisfactory for a second line treatment: omeprazole, azithromycin, amoxycillin, and colloidal bismuth subcitrate for two weeks (81% PP, 77% ITT) 40 ; omeprazole, metronidazole, amoxycillin, and bismuth citrate for two weeks (82% PP, 70% ITT). 41 However, in both studies no data on the initial treatment or the pattern of microbial resistance after treatment failure were given. The former therapy was reported to be linked to a side eVect rate of 41%. 40 Moreover, the question of safety of quadruple therapy was further raised by Phillips et al, 42 reporting high blood levels of bismuth in two of eight patients after co-administration of colloidal bismuth subcitrate and omeprazole for two to four weeks, but not after bismuth subnitrate/ carbonate and omeprazole.
Is treatment eYcacious and cost-eVective in routine community practice? Two studies ascertained that H pylori eradication rates are similar 43 or even equivalent 44 in the community setting to clinical trials. A cost analysis was performed by Vakil and Fennerty 43 using a decision tree model with a follow up period of two years. The costs are dominated by cases of failed eradication, but not by the initial costs of treatment. Therefore highly eYcacious treatments such as PPI based triple therapies resulted in the lowest total costs, the triple therapy with a PPI, clarithromycin, and metronidazole being the most cost-eVective. Regimens with eradication rates of less than 90% are not cost-eVective in routine practice.
Is treatment eYcacy dependent on disease entity?
The GU-Mach study 6 and also the study by Katicic et al 16 confirmed comparable H pylori eradication rates in the treatment of gastric and duodenal ulcer. 7 Comparing H pylori eradication in peptic ulcer disease and non-ulcer dyspepsia, two studies 19 32 detected lower eradication rates in the treatment of non-ulcer dyspepsia. No possible reasons are given, but lower compliance may be the cause. Georgopoulos et al 45 found no diVerence between ulcer disease and non-ulcer dyspepsia, but lymphoid follicles were a negative predictor of treatment success. Again, it was confirmed that healing of uncomplicated duodenal ulcer is achieved by an eVective one week H pylori treatment without consecutive acid suppression. 9 46-49 In contrast, gastric ulcer healing may take a long time despite continued PPI therapy. 6 47 What is the impact of microbial resistance? The reported prevalences of pretreatment resistance were similar to previous reports from Europe: macrolide resistance about 2-3%; nitroimidazole resistance about 30%. 4 23 50 51 Exceptions were metronidazole resistance in Greece of 44%, 45 macrolide resistance in France of 10.5% 21 or about 15%, 29 and an increase in macrolide resistance in Portugal from 5.6% (1990-1993) to 11.2% (1994) (1995) (1996) (1997) in the past seven years. 51 The impact of metronidazole resistance on eradication rates was confirmed. In the face of metronidazole resistance, H pylori eradication rates were 75% 4 and 74% 50 when a triple therapy with PPI, clarithromycin, and metronidazole was used, and 62% when a four day quadruple therapy was used. 34 In a dual antibiotic treatment without a PPI, the impact of metronidazole resistance is considerably greater. 4 Poor eradication of less than 50% ensues when clarithromycin resistance is present. 4 50 In contrast, Mégraud et al 29 reported an H pylori cure rate of 11 in 12 cases with clarithromycin resistant strains using dual therapy with clarithromycin and ranitidine bismuth citrate.
Again confirmed, although in small numbers, was the occurrence of post-treatment resistance to clarithromycin in 50% 4 or more 50 52 of cases with failure after macrolide containing regimens.
Whereas second line treatment of patients with persistent H pylori infection after dual therapy with omeprazole and amoxycillin is highly eYcacious with triple therapy, 8 second line treatment after failure of triple therapy still yields inconsistent and partly unsatisfactory results. The recommended quadruple therapy with PPI, bismuth, metronidazole, and tetracyclin led to eradication rates of 72%, 53 50%, 52 and 93%, 17 whereas with the modified quadruple therapies mentioned above the eradication rates were higher (81%, 40 82% and 86%
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). Almost all of the studies on second line therapies specified neither the initial therapy nor the pattern of resistance after initial treatment failure. Obviously, the success of the second line treatment depends on the components of the initial treatment. 54 Thus no general conclusion can be drawn from the studies presented on second line treatments. However, it has been confirmed that it is of benefit to determine the resistance status before planning the second line treatment. 50 52 A small study 55 reported a 75% eradication rate with omeprazole, amoxycillin, and ciprofloxacin in cases with double resistance against clarithromycin and metronidazole. This needs further confirmation, as previous experience with ciprofloxacin in H pylori eradication therapy has been very poor. 
